Browsing ICR Divisions by author "Parker, Chris"
Now showing items 21-40 of 40
-
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.
Kishan, AU; Tendulkar, RD; Tran, PT; Parker, CC; Nguyen, PL; et al. (2018-05-15)Context Currently, salvage radiotherapy (SRT) is the only known curative intervention for men with recurrent disease following prostatectomy. Critical issues in the optimal selection and management of men being considered ... -
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
Gulley, JL; Borre, M; Vogelzang, NJ; Ng, S; Agarwal, N; et al. (2019-05)PURPOSE:PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further ... -
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Parker, C; Castro, E; Fizazi, K; Heidenreich, A; Ost, P; et al. -
Prostate radiotherapy in newly diagnosed metastatic prostate cancer.
Ali, A; Parker, CC; Clarke, NWPurpose of review The aim of this article is to review the role of prostate radiotherapy in the multimodal management of newly diagnosed metastatic hormone naïve prostate cancer.Recent findings Two randomized controlled ... -
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.
Stavrinides, V; Norris, JM; Karapanagiotis, S; Giganti, F; Grey, A; et al. (Radiological Society of North America (RSNA), 2022-12-13)Background The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific antigen (PSA) level and no previous biopsy. Purpose To assess ... -
Reply from Authors re: Tillmann Loch, Pat Fox Fulgham. Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow. Eur Urol 2016;69:1034-6: Imaging in Active Surveillance for Prostate Cancer: Where Should We Focus Our Research?
Henderson, DR; de Souza, NM; Parker, CC; van As, NJ (2016-06) -
Salvage Treatment After Radical Prostatectomy.
Parker, C; Sydes, MR (2018-02) -
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
Targeted Alpha Therapy Working Group; Parker, C; Lewington, V; Shore, N; Kratochwil, C; et al. (2018-12)Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types.Observations ... -
The Emerging Role of Local Therapy in Metastatic Prostate Cancer.
Sundahl, N; Tree, A; Parker, C (2020-01-20)PURPOSE OF REVIEW:This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer. RECENT FINDINGS:The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a ... -
The potential of <sup>223</sup>Ra and <sup>18</sup>F-fluoride imaging to predict bone lesion response to treatment with <sup>223</sup>Ra-dichloride in castration-resistant prostate cancer.
Murray, I; Chittenden, SJ; Denis-Bacelar, AM; Hindorf, C; Parker, CC; et al. (2017-10)Purpose The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of 223 Ra-dichloride, to assess the relationship between those doses and corresponding 18 F-fluoride ... -
The role of lifestyle characteristics on prostate cancer progression in two active surveillance cohorts.
Vandersluis, AD; Guy, DE; Klotz, LH; Fleshner, NE; Kiss, A; et al. (2016-09)Background Although much research has examined the relationship between lifestyle and prostate cancer (PCa) risk, few studies focus on the relationship between lifestyle and PCa progression. The present study examines this ... -
The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Wilson, JM; Parker, C (2016-09)Introduction A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for men with ... -
Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation.
Yun Ooi, K; Pereira, I; Nagar, H; Simcock, R; Katz, MS; et al.<h4>Background</h4>Management of prostate cancer after surgery is controversial. Past studies on adjuvant radiotherapy (aRT) for higher-risk features have had conflicting results. Through the collaborative conversations ... -
Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance.
Guy, DE; Vandersluis, A; Klotz, LH; Fleshner, N; Kiss, A; et al. (2018-06)BACKGROUND:Research examining the association between physical activity (PA) and prostate cancer (PCa) has accumulated; however, few studies have examined this association in the context of active surveillance. The current ... -
The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers.
Ball, RY; Cardenas, R; Winterbone, MS; Hanna, MY; Parker, C; et al. (2021-11-03)The Prostate Urine Risk (PUR) biomarker is a four-group classifier for predicting outcome in patients prior to biopsy and for men on active surveillance. The four categories correspond to the probabilities of the presence ... -
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.
Norris, JM; Carmona Echeverria, LM; Bott, SRJ; Brown, LC; Burns-Cox, N; et al.Background All risk stratification strategies in cancer overlook a spectrum of disease. The Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore cancers that are overlooked by multiparametric magnetic ... -
When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers.
Stavrinides, V; Parker, CC; Moore, CM (2017-07)Although the incidence of prostate cancer is rising due to PSA screening and increased life expectancy, the metastatic potential of low-grade, organ-confined disease remains low. An increasing number of studies suggest ...